Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren’s syndrome versus non-Sjogren’s syndrome

2021 ◽  
Author(s):  
Mehmet Ozgur Cubuk ◽  
Ahmet Yucel Ucgul ◽  
Armagan Ozgur ◽  
Kemal Ozulken ◽  
Erdem Yuksel
Keyword(s):  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Cyclosporine A ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Comparison Study ◽  
Sjögren‘S Syndrome

scholarly journals Assessment of the Compliance with 0.1% Cyclosporine A in Dry-Eye Patients with Sjögren's Syndrome

2021 ◽  
Vol 62 (7) ◽  
pp. 895-903
Author(s):  
Do Hee Park ◽  
Hyung Nam Jin ◽  
Hee Su Yoon ◽  
Hyeon Jeong Yoon ◽  
Kyung-Chul Yoon
Keyword(s):  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Cyclosporine A ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Eye Drops ◽  
Eye Symptoms ◽  
Dry Eye Symptoms ◽  
Sjögren‘S Syndrome

Purpose: To evaluate the compliance with 0.1% cyclosporine A in dry eye patients with Sjögren's syndrome and identify factors affecting the compliance. Methods: This study included 67 dry eye patients with Sjögren's syndrome who had used 0.1% cyclosporine A for over 6 months. Clinical parameters including sex, age, the number of eye drops used, side effects, the use of steroid eye drops, and the visit interval were investigated. Additionally, the ocular surface disease index, tear break-up time (TBUT), Schirmer test score, and corneal fluorescein staining (CFS) score were assessed. Patients were classified into compliant and non-compliant groups, using a criterion of 50% compliance; relevant factors were evaluated accordingly. Results: Of the 67 patients, 36 (53.7%) were classified into the compliant group and 31 (46.3%) into the non-compliant group. Compared to the non-compliant group, the compliant group showed a longer TBUT (p = 0.03) and a lower CFS score (p = 0.04) at 6 months of follow-up. Altogether, 39 subjects (58.2%) experienced side effects, of which the most common was stinging pain (71.8%). In the multivariate analysis, severe dry-eye symptoms (p = 0.03), non-use of the steroid eye drops (p = 0.02), and longintervals between exam vitists (p = 0.02) were identified as factors reducing compliance. Conclusions: Factors related to a decrease in the compliance with 0.1% cyclosporine A in dry-eye patients with Sjögren's syndrome, included severe dry eye symptoms, long visit intervals, and non-use of steroid eye drops. Taking these factors into consideration may help increase patient compliance.

Tear metabolomics highlights new potential biomarkers for differentiating between Sjögren's syndrome and other causes of dry eye

2021 ◽  
Author(s):  
Geoffrey Urbanski ◽  
Sophie Assad ◽  
Floris Chabrun ◽  
Juan Manuel Chao de la Barca ◽  
Odile Blanchet ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Potential Biomarkers ◽  
Sjögren‘S Syndrome

scholarly journals SNP variations in IL10, TNFα and TNFAIP3 genes in patients with dry eye syndrome and Sjogren’s syndrome

2019 ◽  
Vol 16 (1) ◽  
Author(s):  
Hadas Ben-Eli ◽  
Nir Gomel ◽  
Doron Jacob Aframian ◽  
Rania Abu-Seir ◽  
Riki Perlman ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Dry Eye Syndrome ◽  
Sjögren‘S Syndrome

Treatment of Sjögren's Syndrome–Associated Dry Eye

Ophthalmology ◽  
2011 ◽  
Author(s):  
Esen Karamursel Akpek ◽  
Kristina B. Lindsley ◽  
Rohit S. Adyanthaya ◽  
Ramya Swamy ◽  
Alan N. Baer ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Dry Eye ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Sjögren‘S Syndrome
Sign in / Sign up

Export Citation Format

Share Document